Genomic Health Anticipates Breast Cancer Test Growth in Europe, Preps More Data on Prostate Assay | GenomeWeb

Originally published May 13.

NEW YORK (GenomeWeb) — Genomic Health said that it anticipates continued adoption of its flagship Oncotype DX breast cancer test outside the US this year, and it is planning to share several studies in coming months supporting the expanded use of that test. Company officials also discussed during a call describing first quarter earnings last week efforts to build the evidence base for, and drive adoption of, its new prostate cancer diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.